Development and evaluation of extended release metformin pellets suspended in teneligliptin jelly for the treatment of diabetes mellitus
During chronic treatment of diabetes mellitus, a few patients may need combination therapy with metformin hydrochloride (MH). Such combinations are available in the form of tablets. However, the size of these tablets is large and may lead to difficulty in swallowing, especially in case of geriatric and dysphagic patients.
To help such patients, an alternate dosage form such as an oral jelly of teneligliptin in immediate release form containing MH in extended release may offer better convenience. The current research focuses on development of oral jelly to provide palatable, unit dose, easy to swallow, easy to carry pouches, having similar in vitro profile against marketed tablets. The developed oral jelly formulation is optimized using design of experiments.
The objective of present work is to develop and characterize dual release jelly formulation containing teneligliptin in immediate release form and MH in the form of an extended release pellets for the treatment of diabetes mellitus to improve patient compliance.
Article information: Shailesh Kulkarni, Vaishali Y. Londhe, Development and evaluation of extended release metformin pellets suspended in teneligliptin jelly for the treatment of diabetes mellitus, Journal of Drug Delivery Science and Technology, Volume 70, 2022. https://doi.org/10.1016/j.jddst.2022.103192.